Log in

NASDAQ:SEEL - Seelos Therapeutics Stock Price, Forecast & News

-0.03 (-3.45 %)
(As of 02/28/2020 01:35 AM ET)
Today's Range
Now: $0.84
50-Day Range
MA: $1.13
52-Week Range
Now: $0.84
Volume501,700 shs
Average Volume830,797 shs
Market Capitalization$22.70 million
P/E RatioN/A
Dividend YieldN/A
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SEEL



Sales & Book Value

Annual SalesN/A
Book Value$2.73 per share


Net Income$-9,240,000.00


Market Cap$22.70 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

What price target have analysts set for SEEL?

3 equities research analysts have issued 1-year price targets for Seelos Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Seelos Therapeutics' stock price to reach $5.33 in the next year. This suggests a possible upside of 534.9% from the stock's current price. View Analyst Price Targets for Seelos Therapeutics.

What is the consensus analysts' recommendation for Seelos Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seelos Therapeutics.

Has Seelos Therapeutics been receiving favorable news coverage?

Headlines about SEEL stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Seelos Therapeutics earned a news impact score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View News Stories for Seelos Therapeutics.

Are investors shorting Seelos Therapeutics?

Seelos Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,190,000 shares, an increase of 13.3% from the January 15th total of 1,050,000 shares. Based on an average daily volume of 519,700 shares, the short-interest ratio is currently 2.3 days. Currently, 5.9% of the shares of the company are sold short. View Seelos Therapeutics' Current Options Chain.

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), TrovaGene (TROV), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Aduro BioTech (ADRO), AzurRx BioPharma (AZRX), Oncolytics Biotech (ONCY) and Selecta Biosciences (SELB).

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the folowing people:
  • Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.14%). View Institutional Ownership Trends for Seelos Therapeutics.

Which institutional investors are buying Seelos Therapeutics stock?

SEEL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Seelos Therapeutics.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.84.

How big of a company is Seelos Therapeutics?

Seelos Therapeutics has a market capitalization of $22.70 million. View Additional Information About Seelos Therapeutics.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is http://www.seelostherapeutics.com/.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-998-6475 or via email at [email protected]

MarketBeat Community Rating for Seelos Therapeutics (NASDAQ SEEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote "Outperform" if you believe SEEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel